Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart

Impact · against what's priced in

The dissolution of the Eli Lilly partnership and accompanying 40% workforce reduction are material negative catalysts for Foghorn Therapeutics. Because there is no existing priced-in reconstruction to offset these losses, the impact is driven by the loss of funding and strategic validation.

FOGN−0.70: No priced-in read yet
In context: Price assumptions are unknown due to lack of reconstruction, but the loss of partnership milestones and a 40% job cut represent a significant deterioration in funding and pipeline prospects.
Read from the article alone

Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart

LLY▲73%
biotech
FOGN
cancer research
drug development
partnership dissolution
pharma

Top 1 mover · tap to explore

Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart

What matters in this story

Nasdaq Scores Record High As Oil Falls; Nvidia Hits New Highs

Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart

What matters in this story

Nasdaq Scores Record High As Oil Falls; Nvidia Hits New Highs

How each ticker is affected

Connected tickers

Track these names every morning.

AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment

Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips

Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart

What matters in this story

Next reads from the same story arc

Nasdaq Scores Record High As Oil Falls; Nvidia Hits New Highs

Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart

What matters in this story

Next reads from the same story arc

Nasdaq Scores Record High As Oil Falls; Nvidia Hits New Highs

How each ticker is affected

Connected tickers

Track these names every morning.

AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment

Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips

Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives